AMANDA KEENHOLD: Open Payments
NPI 1013248699 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$923 in 49 payments from 15 companies in 2025. Trend: 2023 $115 · 2024 $938 · 2025 $923
Food & beverage: $923
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $238 |
| Lundbeck LLC | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 3 | $73 |
| Braeburn Inc. | 3 | $64 |
| Alkermes, Inc. | 3 | $62 |
| Indivior Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Qelbree, BRIXADI, ARISTADA, ABILIFY MAINTENA, SUBLOCADE.
Industry payments across AZ — which companies pay providers there.
